インビトロフィブリノリチ治療後の血小板依存型トロンビン生成
D L Aronson1, P Chang, C M Kessler
1George Washington University Medical Center, Washington, D.C. 20037.
Circulation
|May 1, 1992
まとめ
rt-PAのような繊維分解剤は,血小板を直接活性化し,血栓生成を増加させ,潜在的にレトロンボシスに寄与する可能性があります. これは,プラズミノゲン活性化とは独立した直接的な血小板効果を示唆しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 血液学 ヘマトロジ
- 心血管科学の研究について
背景:
- 線維解毒剤療法 (fibrinolytic therapy) は,血栓症の治療に不可欠であるが,レトロンボシスと関連している.
- 証拠によると,凝固と血小板活性化の増加の両方が,この現象に寄与していることを示唆しています.
研究 の 目的:
- 血小板活性化と血栓生成に対するフィブリノリチス剤の直接的な効果を調査する.
- 線維解毒剤がプラズミノゲンとは独立して血小板機能に直接影響するかどうかを判断する.
主な方法:
- 血小板豊富な血 (PRP) と洗浄された血小板は,ウロキナーゼ,再結合組織型プラズミノゲン活性化剤 (rt-PA),またはプラズミンでインキュベートされました.
- トロンビン生成と凝固時間は,治療されたおよび未治療のPRPとプラズマで測定されました.
- 洗浄された血小板をフィブリノリチス剤で処理し,血小板が少ないプラズマに加え,血小板がトロンビン生成を支えているかどうかを評価した.
主要な成果:
- フィブリノリチス剤は,PRPにおけるトロンビン生成を加速し,凝固時間を短縮しました.
- 再結合組織型プラズミノゲン活性化剤 (rt-PA) とプラズミンは,ウロキナーゼではなく,洗浄された血小板がトロンビン生成をサポートする能力を高めました.
- rt-PAの血小板に対するプロ凝固効果は,プラズミノゲンがない場合でも観察されました.
結論:
- プラズミンは,プロトロンビン活性化の血小板支持を直接増加させます.
- 再結合組織型プラズミノゲン活性化剤 (rt-PA) は,プラズミノゲンとは独立して,血小板に直接影響を及ぼし,血栓生成を強化することができます.
- これらの発見は,線維解毒剤による直接的な血小板活性化メカニズムを強調し,治療後のレトロンボシスを説明する可能性がある.
さらに関連する動画
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.